Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor coordination are typical symptoms of Parkinson's. The symptoms may develop slowly, and it sometimes takes time to make a correct diagnosis.

Researchers at the Department of Global Public Health and Primary Care (IGS) at the University of Bergen (UiB) have completed a large study that included data from the Norwegian Prescription Database, in cooperation with researchers at Harvard University.

"Our analysis of data from the whole Norwegian population has been decisive for the conclusion in this study," says Professor Trond Riise at IGS. He leads the registery study in Norway.

100 million prescriptions
Together with colleagues Anders Engeland and Kjetil Bjørnevik, Riise has analysed more than 100 million Norwegian prescriptions registered since 2004.

In the study, the treatment of Parkinson's was linked to prescriptions of asthma medicine and the medicine for high blood pressure. It enabled the researchers to see the connection between medicine use and illness.

The UiB-researchers were able to make these comparisons by using the prescription database. The Norwegian analysis was done after researchers at Harvard University found these effects of the medicines in animal tests and in experiments with brain cells in the lab. Their results showed that these different medicines had opposite effects on the risk of Parkinson's.

Possible new treatment
To find out if these medicines had the same effect on humans, the researchers at Harvard University started to collaborate with the Norwegian research team, and their unique resource of having access to the unique and large Norwegian database, where all Norwegian prescriptions are registered.

"We analysed the whole Norwegian population and found the same results as in the animal testing at Harvard University. These medicines have never been studied in relation to Parkinson's disease," says Riise.

Trond Riise underlines the fact that "Our discoveries may be the start of a totally new possible treatment for this serious disease. We expect that clinical studies will follow these discoveries."

Shuchi Mittal1, Kjetil Bjørnevik, Doo Soon Im, Adrian Flierl, Xianjun Dong, Joseph J Locascio1, Kristine M Abo, Elizabeth Long, Ming Jin, Bing Xu, Yang K Xiang, Jean-Christophe Rochet, Anders Engeland, Patrizia Rizzu, Peter Heutink, Tim Bartels, Dennis J Selkoe, Barbara J Caldarone, Marcie A Glicksman, Vikram Khurana, Birgitt Schüle, David S Park, Trond Riise, Clemens R Scherzer.
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.
Science, Vol. 357, Issue 6354, pp. 891-898, doi: 10.1126/science.aaf3934.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]